The influence of nebivolol on central hemodynamic, platelet aggregation and hypophis-honad system in men arterial hypertension
Abstract
Object of this investigation is study of Nebivolol's influence on parameters of Central Hemodynamic, platelet aggregation and levels of hypophis-honad hormones in patients with Arterial Hypertension (AH). 32 patients (men) aged 30-65 years with mild and moderate AH were examined. Nebivolol was administrated in dosage of 5 mg one time daily as the 6 monthly monotherapy. We carried out the dynamic control of Blood Pressure (BP), researched the Central Hemodynamic by Echocardiography, evaluated the aggregative activity of thrombocytes and also defined levels of the Follicle-Stimulating Hormone (FSH), Luteinzing Hormone (LH), testosterone (T) in patient's serum before and after treatment. Against background 6-monthly therapy we have revealed, that systolic BP decreased from 152,0±2,44 mm of mercury column (m.c.) to 128,0±1,72 mm m.c. diastolic BP-from 104,0±1,42 mm m.c. to 78,0±1,34 mm m.c. (p<0.05), the Miocardial Mass was reduced on 10%; terminal diastolic Volume decreased from 134,3±7,4ml to 107,5±6,3ml, at the same time the Ejection Fraction increased from 58,4±3,6% to 66,5±3,4%. Patients with AH had higher rate of spontaneous (0.75±0.37) and induced aggregation (2.69±1.23 and 0.83±0.30). But the therapy of Nebivolol decreased the aggregative activity of thrombocytes significantly: spontaneous aggregation became 0.59±0.32 and induced one-1.72±1.18 and 0.66±0.29. In the result of treatment the values of FSH and LH were reduced average on 0,1-0,7 Iu/l, the level of T raised on 0,2-0,6 ngr/ml, that lead to improving of sexual function in men. Thus, the results of our investigation demonstrated, that Nebivolol reduced systolic and diastolic DP effectively, improved paramaters of Central hemodynamic and the aggregation of thrombocytes, increased the level of testosterone and it was reflected of sexual function in men with AH positively.